Cargando…
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
BACKGROUND: Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis. METHODS: Per...
Autores principales: | Francisci, Daniela, Pirro, Matteo, Schiaroli, Elisabetta, Mannarino, Massimo R, Cipriani, Sabrina, Bianconi, Vanessa, Alunno, Alessia, Bagaglia, Francesco, Bistoni, Onelia, Falcinelli, Emanuela, Bury, Loredana, Gerli, Roberto, Mannarino, Elmo, De Caterina, Raffaele, Baldelli, Franco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446135/ https://www.ncbi.nlm.nih.gov/pubmed/30968058 http://dx.doi.org/10.1093/ofid/ofz112 |
Ejemplares similares
-
Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy
por: Pirro, Matteo, et al.
Publicado: (2016) -
Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial
por: Pirro, Matteo, et al.
Publicado: (2016) -
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism
por: Pirro, Matteo, et al.
Publicado: (2017) -
Role of maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced
por: Cipriani, S, et al.
Publicado: (2012) -
Exploring the Link between Plasma Levels of PCSK9, Immune Dysregulation and Atherosclerosis in Patients with Primary Sjögren’s Syndrome
por: Bianconi, Vanessa, et al.
Publicado: (2023)